RESUMO
INTRODUCTION: Pulmonary endoscopy occupies a central role in Interventional Pulmonology and is frequently the mainstay of diagnosis of respiratory disease, in particular lung malignancy. Older techniques such as rigid bronchoscopy maintain an important role in central airway obstruction. Renewed interest in the peripheral pulmonary nodule is driving major advances in technologies to increase the diagnostic accuracy and advance new potential endoscopic therapeutic options. AREAS COVERED: This paper describes the role of pulmonary endoscopy, in particular ultrasound in the diagnosis and staging of lung malignancy. We will explore the recent expansion of ultrasound to include endoscopic ultrasound - bronchoscopy (EUS-B) and combined ultrasound (CUS) techniques. We will discuss in detail the advances in the workup of the peripheral pulmonary nodule.We performed a non-systematic, narrative review of the literature to summarize the evidence regarding the indications, diagnostic yield, and safety of current bronchoscopic sampling techniques. EXPERT OPINION: EBUS/EUS-B has revolutionized the diagnosis and staging of thoracic malignancy resulting in more accurate assessment of the mediastinum compared to mediastinoscopy alone, thus reducing the rate of futile thoracotomies. Although major advances in the assessment of the peripheral pulmonary nodule have been made, the role of endoscopy in this area requires further clarification and investigation.
RESUMO
INTRODUCTION: The use of ultrasound in respiratory disease has evolved substantially over the past two decades. From a test done to confirm the safe site of pleural fluid drainage, thoracic ultrasound has become a point-of-care test that guides the management of patients on respiratory wards, in clinics and endoscopy. AREAS COVERED: This review overviews the process of ultrasound examination in the chest. It then delves into specific disease areas (pleural disease, lung disease, diaphragm disease, and invasive procedures) to highlight how thoracic ultrasound is being used to refine management. The review concludes with discussion on the training curricula and assessment tools for competency in thoracic ultrasound. Being a scoping review, literature searches were conducted on PubMed using relevant search terms. EXPERT OPINION: In addition to its current uses, there are many avenues where thoracic ultrasound will soon be beneficial. Recent studies show promising roles in areas such as patient-tailored guidance of pleurodesis and non-invasively predicting lung re-expansion after pleural fluid drainage. In addition, auxiliary tools such as contrast-enhanced ultrasound and elastography are proving useful in identifying the etiology and directing the successful sampling of pleural and lung lesions. Studies are also exploring the utility of sonographic biomarkers such as echogenicity and septations to predict outcomes in pleural disease.
Assuntos
Doenças Pleurais , Humanos , Doenças Pleurais/diagnóstico por imagem , Doenças Pleurais/terapia , Pneumopatias/diagnóstico por imagem , Pneumopatias/terapia , Ultrassonografia de Intervenção , Ultrassonografia , Doenças Respiratórias/diagnóstico por imagem , Doenças Respiratórias/terapia , Testes ImediatosRESUMO
BACKGROUND: Smoking rather than injecting heroin has become more common over the last 20 years. Although there is an increasing body of evidence describing high levels of chronic obstructive pulmonary disease (COPD) in people who smoke heroin, there is limited evidence documenting the impact of the long-term condition on this population group. AIM: This study aimed to describe the experiences of people who smoke heroin with COPD in Liverpool, UK. DESIGN & SETTING: Participants were purposefully sampled for this qualitative study. They included adults enrolled in an opioid replacement clinic run by Addaction in Liverpool, who had already engaged with spirometry testing for COPD as part of a previous study. METHOD: Semi-structured interviews were performed with participants with spirometrically confirmed COPD in opioid replacement clinics. Data were analysed using a framework analysis approach. RESULTS: Sixteen potential participants were invited to take part in the study, of which 10 agreed and were interviewed. Three themes common to all interviews were identified: functional measures of lung health that impacted on their activities of daily living; inhaler and medication perceptions with erratic use that was not concordant with their prescription; and the impact of difficulties accessing care. CONCLUSION: These findings, along with previous studies highlighting the prevalence of COPD in this population, warrant efforts to integrate community COPD and opioid replacement services to improve outcomes for this vulnerable population.
RESUMO
BACKGROUND: Heroin smokers have high rates of COPD, respiratory morbidity, hospital admission, and mortality. We assessed the natural history of symptoms and lung function in this population over time. METHODS: A cohort of heroin smokers with COPD was followed for 18 to 24 months. At baseline and follow-up, respiratory symptoms were measured by the Medical Research Council Dyspnea Scale (MRC) and the COPD Assessment Tool (CAT), and postbronchodilator spirometry was performed. Frequency of health-care-seeking episodes was extracted from routine health records. Parametric, nonparametric, and linear regression models were used to analyze the change in symptoms and lung function over time. RESULTS: Of 372 participants originally recruited, 161 were assessed at follow-up (mean age, 51.0 ± 5.3 years; 74 women [46%]) and 106 participants completed postbronchodilator spirometry. All participants were current or previous heroin smokers, and 122 (75.8%) had smoked crack. Symptoms increased over time (MRC score increased by 0.48 points per year, P < .001; CAT score increased by 1.60 points per year, P < .001). FEV1 declined annually by 90 ± 190 mL (P < .001). This deterioration was not associated with change in tobacco or heroin smoking status or use of inhaled medications. CONCLUSIONS: Heroin smokers experience a high and increasing burden of chronic respiratory symptoms and a decline in FEV1 that exceeds the normal age-related decline observed among tobacco smokers with COPD and healthy nonsmokers. Targeted COPD diagnostic and treatment services hosted within opiate substitution services could benefit this vulnerable, relatively inaccessible, and underserved group of people.
Assuntos
Dependência de Heroína/fisiopatologia , Pulmão/fisiopatologia , Doença Pulmonar Obstrutiva Crônica/fisiopatologia , Fumar Produtos sem Tabaco/fisiopatologia , Broncodilatadores/uso terapêutico , Fumar Cigarros/epidemiologia , Fumar Cigarros/fisiopatologia , Fumar Cocaína/epidemiologia , Fumar Cocaína/fisiopatologia , Estudos de Coortes , Progressão da Doença , Serviço Hospitalar de Emergência/estatística & dados numéricos , Feminino , Volume Expiratório Forçado , Dependência de Heroína/tratamento farmacológico , Dependência de Heroína/epidemiologia , Hospitalização/estatística & dados numéricos , Humanos , Estudos Longitudinais , Masculino , Fumar Maconha/epidemiologia , Fumar Maconha/fisiopatologia , Programas de Rastreamento , Pessoa de Meia-Idade , Tratamento de Substituição de Opiáceos , Atenção Primária à Saúde/estatística & dados numéricos , Doença Pulmonar Obstrutiva Crônica/epidemiologia , Índice de Gravidade de Doença , Fumar Produtos sem Tabaco/epidemiologia , EspirometriaRESUMO
With the support of our local Public Health and NHS England teams, we developed a pathway of care to provide seasonal influenza vaccination to our heroin dependent service users. 340 of the 515 service users receiving opioid substitution treatment (OST) were offered the vaccination in the 2014/15 influenza season and 205 accepted it. A further 29 service users received the vaccination elsewhere. With over 50% of those on OST prescriptions known to have a diagnosed chronic condition, such as liver or respiratory disease, this was a worthwhile health intervention in a population that is known to be "hard to reach." In addition to the potential benefit to the individuals who received the seasonal influenza vaccination, there was also an opportunity to provide health advice and information surrounding chronic disease management. Service user feedback overwhelmingly supported the provision of seasonal influenza vaccination within Drug and Alcohol services.
Assuntos
Atenção à Saúde/organização & administração , Usuários de Drogas , Programas de Imunização , Vacinas contra Influenza/administração & dosagem , Influenza Humana/prevenção & controle , Adulto , Idoso , Inglaterra , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Inquéritos e QuestionáriosRESUMO
BACKGROUND: Peritonitis is the major complication of peritoneal dialysis (PD) and has acute morbidity and resources implications. Episodes of peritonitis are associated with higher risk of peritoneal membrane failure. Rapid diagnosis of peritonitis would allow early antibiotic commencement with potential benefits of reduced need for in-patient care and dialysis modality change. This study examined the utility of a rapid peritonitis diagnosis method (Periscreen). METHODS: This was a prospective study in a single unit and included all PD patients presenting with symptoms or signs of peritonitis over 12 months. In each clinical circumstance in which the diagnosis or exclusion of peritonitis was required and in follow-up peritonitis cases, PD fluid was sent for standard laboratory analysis but also tested using the Periscreen strip. The relationship between this rapid diagnostic strip and standard laboratory methods for determination of PD fluid neutrophil count was determined. RESULTS: This study found the Periscreen strip easy to use and interpret. All 17 episodes of peritonitis (defined by ISPD criteria) were detected and results of the strip correlated closely with the laboratory cell count. In this study sensitivity of the Periscreen was 100% and specificity was 98%, positive predictive value was 95.6% and negative predictive value was 100%. Results were equally good in glucose containing fluids and icodextrin. CONCLUSIONS: Periscreen is a sensitive, specific rapid tool for the presumptive diagnosis of peritonitis in PD patients used at the "point of care". Results correlated with the laboratory white cell count, a test that takes longer to perform. Widespread use in PD would aid in the early recognition and treatment of peritonitis.
Assuntos
Diálise Peritoneal/efeitos adversos , Peritonite/diagnóstico , Peritonite/etiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Técnicas de Laboratório Clínico/normas , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Peritonite/epidemiologia , Estudos Prospectivos , Fatores de TempoRESUMO
Nurse education has undergone many changes over the last 30 years in line with the changing expectations of the nurse's role. A review of the literature suggests that nurses are inadequately prepared for their role in medication administration. With the introduction of nurse prescribing, the issue of education in pharmacology is becoming increasingly important. This paper describes a study conducted via a questionnaire survey of all nurse education institutions in England. The aim of the survey was to identify current pharmacology education provided for pre-registration nurses, in terms of curriculum design and content, and also to elicit the personal opinions of those involved in the delivery of nurse education. The results support the notion that many nurses may be inadequately prepared for the role that they are expected to perform once qualified. The reasons for this appear to be complex, though they may include insufficient guidelines from the nursing regulatory bodies, local political difficulties and a lack of consistency between educational establishments.
Assuntos
Educação em Enfermagem , Farmacologia/educação , Atitude , Currículo , Inglaterra , Humanos , Ensino/métodosRESUMO
Schemes for spontaneous reporting of adverse drug reactions are important to post-marketing safety surveillance worldwide. In the UK, doctors, dentists, coroners, and pharmacists are allowed to report through the yellow card scheme, but nurses were not until October, 2002. We used a similar programme to assess the role of community and hospital nurses in reporting of adverse drug reactions. The proportion and quality of reports received from nurses was similar to that of those received from doctors: we received reports from one in seven nurses eligible to report, compared with one in eight doctors; 137 of 177 nurse reports and 676 of 984 doctor reports were judged to be appropriate according to regulatory authority criteria (95% CI for difference between proportions 1.4-15.0, z=2.3, p=0.02). Our findings suggest that nurses, who form the largest proportion of health-care staff in the UK, can play a valuable part in improvement of pharmacovigilance.